Eledon Pharmaceuticals, Inc. ELDN
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Eledon Pharmaceuticals, Inc. (ELDN) is a healthcare company listed in the US with a market value of about $179M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -191%.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 0 of the last 10 years in our data. Its share count rose by 473% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | $0 |
| Net income | -$46M | -$36M | -$117M | -$88M | -$35M | -$23M | -$16M | -$14M | -$13M | -$6M |
| Free cash flow | — | — | — | — | — | — | — | — | — | -$5M |
| EPS (diluted) | $-0.52 | $-0.66 | $-4.73 | $-6.16 | $-2.33 | $-15.72 | $-24.42 | $-28.08 | $-41.40 | $-44.28 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | — | — | -360.4% | -20.9% | -9.5% | -129.5% | -76.6% | -53.3% | -688.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $9.00, 326% above the current price; targets range from $7.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.89 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Eledon Pharmaceuticals pay a dividend?
Not currently.
Is Eledon Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Eledon Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.